Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.
Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...
A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
The dosage of semaglutide in Wegovy is higher than in Ozempic, which is why Wegovy tends to lead to greater weight loss results​​. For those focused purely on weight loss, Wegovy may offer more ...